IPCALAB1,972.10

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹50,032 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)406.99410.46425.26425.26
Receivable Days (DSO)79.8976.5176.2276.22
Payable Days (DPO)127.81135.65146.42145.12
Cash Conversion Cycle (days)359.07351.32355.06356.36
Working Capital Turnover2.422.502.372.49
Asset Turnover0.690.760.780.78
Cash Conversion (CFO/Net Income)1.811.680.960.96
CFO/EBITDA0.720.770.580.58
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.